AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 281 min read$CYTK

Blum Robert I sold $491K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $65.46 ($0.49M total) on 2026-09-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published Sep 28, 2026, 8:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Bearish
medium confidence
Mentioned
$CYTK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKBearishLow
01

Why it matters

The filing provides fresh, material information about insider disposition, which can affect short‑term price dynamics.

02

Market read

Insider sales by top executives are closely watched; this filing may prompt traders to reassess CYTK's near‑term outlook.

03

What to watch

The transaction occurred after a recent positive trial update, which may offset negative sentiment.

Relevance 3/10Novelty 3/10Timing: post‑market today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$CYTKBearishMedium confidence
Context

CEO Robert Blum sold 7,500 shares for $491K via a 10b5‑1 plan, reducing his stake to 278,544 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $491K sale by the CEO is material for a mid‑cap biotech and may be interpreted as reduced confidence, prompting short‑term sell‑offs.

Market effects

Sector

May raise concerns for other small‑cap biotech firms with insider sales.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal; isolated to CYTK shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event under a pre‑arranged 10b5‑1 plan, not a confidence signal.

Key entities

  • company
    Cytokinetics Inc.

    Biopharmaceutical company developing cardiac and skeletal muscle therapeutics.

  • person
    Robert I. Blum

    President & CEO of Cytokinetics, reporting a sale of 7,500 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

OCT 13
$CYTKHigh

Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten In NHCM At HFSA 2026

Cytokinetics (CYTK) presented data from the ACACIA-HCM trial at the HFSA 2026 meeting, showing aficamten improved exercise performance and clinical outcomes in non-obstructive HCM patients. The drug demonstrated significant benefits in exercise capacity, symptom relief, and safety, with 53% of patients showing improvements across multiple domains. CYTK reported a Q2 2026 net loss of $198.8M and $25.3M in aficamten revenue, with cash reserves of $1.7B.

rttnews.com2 min
OCT 12
$CYTKMed

Cytokinetics presents additional aficamten data from trial

Cytokinetics (CYTK) presented additional data from its ACACIA-HCM trial at the Heart Failure Society of America Annual Scientific Meeting. Aficamten showed statistically significant improvements in exercise performance and clinical response in patients with non-obstructive hypertrophic cardiomyopathy. The company plans to submit a supplemental New Drug Application to the FDA this quarter for this indication.

uk.investing.com1 min
OCT 12
$CYTKMed

Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo.

Cytokinetics (CYTK) presented additional data from the ACACIA-HCM trial at the HFSA Annual Scientific Meeting. The study showed aficamten improved exercise performance and safety in non-obstructive HCM patients. Serious heart failure events occurred in 4.7% of aficamten patients vs. 1.2% on placebo. The company plans to submit a supplemental New Drug Application to the FDA this quarter.

stocktitan.net4 min